

1 ***Crocus Sativus* and Its Active Compound, Crocin Inhibits the Endothelial Activation**
2 **and Monocyte-Endothelial Cells Interaction in Stimulated Human Coronary Artery**
3 **Endothelial Cells**

4

5 **Short title: Saffron Inhibits the Endothelial Activation and Monocyte-Endothelial Cells**
6 **Interaction**

7 *Noor Alicezah Mohd Kasim^{1,2,3*}¶, Nurul Ain Abu Bakar^{2&}, Radzi Ahmad^{3&}, Iman Nabilah Abd*
8 *Rahim^{3&}, Thuhairah Hasrah Abdul Rahman^{1,3}¶, Gabriele Ruth Anisah Froemming⁴¶, Hapizah*
9 *Mohd Nawawi^{1,2,3}¶*

10

11 *¹Department of Pathology, ²Institute of Pathology, Laboratory and Forensic Medicine (I-*
12 *PPerForM), ³Faculty of Medicine, Universiti Teknologi MARA, 47000 Sungai Buloh,*
13 *Selangor, Malaysia*

14 *⁴Department of Basic Medical Sciences, Faculty of Medicine and Health Sciences, Universiti*
15 *Malaysia Sarawak, Kota Samarahan, Malaysia*

16 *Corresponding Author

17 Noor Alicezah Mohd Kasim

18 Email: alicezah_80@yahoo.com

19

20 **Abstract**

21 *Crocus sativus L.* or saffron has been shown to have anti-atherogenic effects. However, its
22 effects on key events in atherogenesis such as endothelial activation and monocyte-

23 endothelial cell binding in lipopolysaccharides (LPS)-stimulated *in vitro* model have not been
24 extensively studied. **Objectives:** To investigate the effects of saffron and its bioactive
25 derivative crocin on the gene and protein expressions of biomarkers of endothelial activation
26 in LPS stimulated human coronary artery endothelial cells (HCAECs). **Methodology:**
27 HCAECs were incubated with different concentrations of aqueous ethanolic extracts of
28 saffron and crocin together with LPS. Protein and gene expressions of endothelial activation
29 biomarkers were measured using ELISA and qRT-PCR, respectively. Adhesion of monocytes
30 to HCAECs was detected by Rose Bengal staining. Methyl-thiazol-tetrazolium assay was
31 carried out to assess cytotoxicity effects of saffron and crocin. **Results:** Saffron and crocin up
32 to 25.0 and 1.6 µg/ml respectively exhibited >85% cell viability. Saffron treatment reduced
33 sICAM-1, sVCAM-1 and E-selectin proteins (concentrations: 3.13, 6.25, 12.5 and 25.0 µg/ml;
34 3.13, 12.5 and 25.0 µg/ml; 12.5 and 25.0, respectively) and gene expressions (concentration:
35 12.5 and 25.0 µg/ml; 3.13, 6.25 and 25.0 µg/ml; 6.25, 12.5 25.0; respectively). Similarly,
36 treatment with crocin reduced protein expressions of sICAM-1, sVCAM-1 and E-selectin
37 (concentration: 0.2, 0.4, 0.8 and 1.6 µg/ml; 0.4, 0.8 and 1.6 µg/ml; 0.8 and 1.6 µg/ml;
38 respectively] and gene expression (concentration: 0.8 and 1.6 µg/ml; 0.4, 0.8 and 1.6 µg/ml;
39 and 1.6 µg/ml, respectively). Monocyte-endothelial cell interactions were reduced following
40 saffron treatment at concentrations 6.3, 12.5 and 25.00 µg/ml. Similarly, crocin also
41 suppressed cellular interactions at concentrations 0.04, 0.08, 1.60 µg/ml. **Conclusion:** Saffron
42 and crocin exhibits potent inhibitory action for endothelial activation and monocyte-
43 endothelial cells interaction suggesting its potential anti-atherogenic properties.

44

45 **Keywords**

46 *Crocus sativus*; Saffron; Crocin; Endothelial activation; Monocyte binding

47

48 **Introduction**

49 Cardiovascular disease (CVD) is currently the leading cause of death in Malaysia with a
50 percentage increase of 37.4% since 2007 (1). In Malaysia, CVD has been the leading cause
51 among the five principals of morbidity and mortality; ischemic heart diseases (13.9%),
52 pneumonia (12.7%), cerebrovascular diseases (7.1%), transport accidents (4.6%) and
53 malignant neoplasm of trachea, bronchus and lung (2.3%) in 2017 (1,2). About 37 deaths per
54 day due to CVD as compared to 24 deaths in 2007. Moreover, CVD is the principal cause of
55 death among Malaysian men, aged 41 to 59 years old in urban areas (2). The major risk
56 factors that cause CVD are smoking, high cholesterol level in blood, obesity and stress (3).
57 The high death rate of atherosclerosis is owing primarily to the fact that it is a multifactorial
58 disease. Therefore, research in recent years has very much skewed towards prevention of
59 atherosclerosis.

60

61 Atherosclerosis is the underlying pathophysiology of CVD. Atherosclerosis was initially
62 thought to be a degenerative disease which was an inevitable consequence of aging (4).
63 Research in the last two decades, however, has shown that atherosclerosis is a multifactorial
64 disease that encompasses both genetic and environmental factors (5). Atherosclerosis is a
65 chronic inflammatory disease of the arteries, which is characterised by infiltration of
66 leukocytes, deposition of lipids and thickening of vascular wall (6). Cellular and molecular
67 events in the pathogenesis of atherosclerosis involves endothelial dysfunction due to an
68 increase in endothelial activation biomarkers [soluble intercellular adhesion molecule-1
69 (sICAM-1), soluble vascular cellular adhesion molecule (sVCAM-1) and E-selectin]
70 infiltration of monocytes, differentiation of monocytes into tissue resident macrophages and

71 smooth muscle cell proliferation (7). The hallmark of atherosclerosis is the accumulation of
72 cholesterol in the arterial wall, particularly cholesterol esters (8). Oxidised low-density
73 lipoprotein (ox-LDL) plays an important role in the initiation and progression of
74 atherosclerosis. The ox-LDL, recognised by scavenger receptors, is then taken up by the
75 macrophages to form foam cells. These foam cells constitute a major source of secretory
76 products that promote further progression of the atherosclerotic plaque (9).

77

78 Natural products that contain bioactive components, have been described to provide desirable
79 health benefits beyond basic nutrition and are practically useful in the prevention of chronic
80 diseases such as CVD and cancer (10). Saffron is a carotenoid-rich spice and also known as
81 the ‘golden spice’ owing to its unique aroma, colour and flavour. It is derived from dried
82 elongated stigma styles of a blue-purple flower, *Crocus sativus* L., traditionally used for
83 several medicinal purposes such as a remedy for kidney problems, stomach ailments,
84 depression, insomnia, measles, jaundice, cholera etc. in different parts of the world (11,12).

85

86 Four major compounds have been identified to be responsible in the health benefit profile of
87 saffron. These compounds are crocin (colour), crocetin - central core of crocin, (colour),
88 picrocrocin (taste) and safranal (aroma). Researchers have reported potential health benefits
89 of these bioactive compounds (13). Crocin is a natural anti-oxidant with multi-unsaturated
90 conjugate olefin acid structure. The compound exhibits favourable effects in the prevention
91 and treatment of a variety of diseases which include dyslipidaemia, atherosclerosis,
92 myocardial ischemia, haemorrhagic shock, cancer and arthritis (14). A study by Sheng et al.,
93 demonstrated inhibition of pancreatic lipase in rats by crocin (15). In addition, it has also been
94 shown to inhibit formation of atherosclerosis in quails (16). These findings highlight the

95 potential anti-atherogenic effects of crocin. However, studies to substantiate these effects at
96 the cellular and molecular level remain scarce.

97

98 Therefore, this study aims to determine the role of crocin on atherogenesis at cellular level by
99 examining its effects on the gene and protein expressions of biomarkers of endothelial
100 activation and monocyte-cellular adhesion activity *in vitro*.

101

102 **Materials and Methods**

103 **Cell culture**

104 Human coronary artery endothelial cells (HCAECs) from Lonza, Switzerland were cultured in
105 endothelial cell basal medium (EBM) supplemented with endothelial cell growth media
106 (EGM) kits in 25cm² flasks and incubated at 37°C in humidified 5% CO₂ environment. The
107 culture medium was replaced every 2 days until the cells were confluent. Cells with 80 to
108 85% confluency and only from passage 6 were used for the experiments.

109

110 **Preparation of crude extract**

111 Saffron crude extract was prepared by dissolving 1g saffron dried filament (Sigma, Germany)
112 into 10 ml of 75% ethanol and mixed thoroughly in supersonic water bath for 2 hours. The
113 mixture then, was filtered and evaporated at 40°C and freeze dried to remove excessive
114 ethanol and water (17). Saffron crude extract stocks of 0.2 g/ml and crocin (Sigma, Germany)
115 stocks of 0.2 g/ml were dissolved in ethanol. The stocks were further diluted with treatment
116 medium containing a mixture of 89% of RPMI-1640 (Sigma, Germany), 10% fetal bovine

117 serum (FBS) (Gibco, USA) and 1% Streptomycin-penicillin to get working concentration of
118 200 µg/ml saffron crude extract and 200 µg/ml crocin with ethanol percentage less than 0.1%.

119

120 **Cell viability testing**

121 Cell viability of HCAECs against saffron crude extract and crocin were tested using (3-(4, 5-
122 Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (Invitrogen, USA), known as MTT
123 assay. The HCAECs were seeded into 96 wells culture plate (1×10^4 cells/well) and treated
124 with various concentrations of saffron crude extract and crocin ranging from 1.6 to 400 µg/ml
125 and 0.4 to 200 µg/ml respectively. The cells were incubated at 37°C for 24 hours in
126 humidified 5% CO₂ environment. Untreated cells were included as control wells. Then, 20 µl
127 MTT solution (5 mg/ml MTT) was added to each well and incubated at 37°C for another 4
128 hours. The supernatant was then removed and replaced with 100 µl DMSO to dissolve the
129 insoluble purple formazan product formed after previous incubation into a coloured solution,
130 followed by 10 to 15 minutes incubation at room temperature. The absorbance was measured
131 at 540 nm using a microplate reader (Tekan, Switzerland). The viability of the cells was
132 measured by comparing the treated wells with the control wells and calculated using the
133 following formula:

134

$$\text{Cell viability (\%)} = \frac{\text{Sample absorbance} - \text{Blank absorbance}}{\text{Control absorbance} - \text{Blank absorbance}} \times 100$$

135

136 **Procarta cytokine analysis**

137 Concentration of sICAM-1, sVCAM-1 and E-selectin were determined by measuring the
138 protein expression for each respective biomarker in the supernatant of lipopolysaccharides
139 (LPS)-stimulated treated HCAECs using Procarta Cytokine Assay Kit (Affimatrix, USA),

140 bead based multiplex assay kit. All procedures were performed according to the
141 manufacturer's instruction and the signal is read using a Luminex instrument.

142

143 **Quantitative reverse transcription (qRT)-PCR analysis**

144 HCAECs were harvested and extracted with RNeasy mini kit (Qiagen, USA). Concentration
145 and purity of the total RNA was determined by Nanodrop and Agilent 2100 Bioanalyzer
146 (Agilent, USA). Sensiscript reverse transcription kit (Bio-rad, USA) was used to reverse
147 transcribe and amplify the RNA into cDNA. Oligonucleotide primers for ICAM-1, VCAM-1,
148 E-selectin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased from
149 Vivantis, USA while iQTM SYBR[®] Green Supermix from Bio-rad, USA was used for
150 quantitative assay. Real time PCR was performed on CFX96 in triplicates and normalised on
151 the basis of their GAPDH content.

152

153 **Monocyte-endothelial interaction**

154 HCAECs (Lonza, USA) were stimulated with LPS and treated with saffron and crocin
155 extracts (Sigma, USA) at different concentrations ranging from 0.05 - 25.00 µg/ml and 0.001
156 - 1.600 µg/ml respectively. They were incubated for 16 hours. Monocyte U937 cell line
157 (ATCC, USA) was added and incubated for 1 hour. 0.25% rose bengal was added and
158 phosphate buffer solution (PBS) containing 10% FBS was used to remove the unbound cells.
159 Ethanol:PBS (1:1) solution was used to stop the reaction. The absorbance was measured by
160 spectrophotometer.

161

162 **Statistical analysis**

163 All data were expressed as mean \pm SD. Differences between groups were assessed by
164 independent T-Test with SPSS (version 22, USA). The level of statistical significance was at
165 $p < 0.05$.

166

167 **Results**

168 **Effect of saffron and crocin on viability of HCAECs**

169 **Fig 1(A)** demonstrates the viability of HCAECs following treatment with different
170 concentrations of saffron ranging from 1.6 to 400.0 $\mu\text{g/ml}$, while **Fig 1(B)** shows the viability
171 of HCAECs following treatment with different concentrations of crocin ranging from 0.4 to
172 200.0 $\mu\text{g/ml}$. Saffron and crocin concentrations of up to 25.0 $\mu\text{g/ml}$ and 1.6 $\mu\text{g/ml}$,
173 respectively gave more than 85% cell viability. Therefore, saffron concentration up to 25.0
174 $\mu\text{g/ml}$ and crocin concentration up to 1.6 $\mu\text{g/ml}$ was used for endothelial activation marker
175 study.

176 **Fig 1. (A) Percentage (%) of human coronary artery endothelial cells (HCAECs)**
177 **viability following treatment with various concentrations of saffron crude extracts**
178 **(1.6–400.0 $\mu\text{g/ml}$) and (B) crocin (0.4–200 $\mu\text{g/ml}$). Data are expressed as mean \pm SD.**

179

180 **Effects of saffron and crocin on protein expression of endothelial**
181 **activation markers; sICAM-1, sVCAM-1 and E-selectin**

182 ELISA kit was used to measure concentration of sICAM-1, sVCAM-1 and E-selectin
183 expressed in the culture medium. The effects of saffron and crocin on endothelial activation
184 markers were determined by comparing the concentration of each soluble molecule from
185 treated LPS-stimulated sample with untreated LPS-stimulated sample. **Fig 2(A)** shows
186 sICAM-1 levels significantly decreased following treatment of saffron and crocin at all doses
187 [concentration: 3.13, 6.25, 12.5 and 25.0 µg/ml; 0.2, 0.4, 0.8 and 1.6 µg/ml. In **Fig 2(B)**,
188 sVCAM-1 reduced following treatment with saffron at concentrations 3.13, 6.25 and 25.0
189 µg/ml ($p < 0.05$) and crocin at 0.8 and 1.6 µg/ml ($p < 0.01$). Untreated and non-stimulated
190 sample served as negative control in this assay for validation. **Fig 2(C)** showed that E-selectin
191 was reduced at higher doses of saffron (12.5 and 2.5 µg/ml) and crocin (0.4, 0.8 and 1.6
192 µg/ml) ($p < 0.01$).

193
194 **Fig 2. Effects of various concentrations of saffron crude extract (3.1.-25.0 µg/ml) and**
195 **crocin (0.2-1.6 µg/ml) on (A) sICAM-1, (B) sVCAM-1 and (C) E-selectin protein**
196 **expressions in HCAECs.** Data are expressed as mean \pm SD. * $p < 0.05$ and ** $p < 0.01$
197 compared to positive control. LPS; lipopolysaccharides, HCAECs; human coronary artery
198 endothelial cells.

199 **Effects of saffron and crocin on gene regulation of endothelial** 200 **activation markers; ICAM-1 VCAM-1 and E-selectin**

201 CFX96 was used to measure ICAM-1, VCAM-1 and E-selectin gene regulation
202 quantitatively from extracted HCAECS. Each sample was normalised to GAPDH gene and
203 effects of saffron and crocin on gene regulation were determined by comparing treated
204 samples with untreated LPS-stimulated sample. **Fig 3(A)** shows significant down-
205 regulation of ICAM-1 gene after treated with saffron at doses of 12.5 and 25.0 µg/ml (p
206 <0.05). Similarly, ICAM-1 gene reduced after treated with crocin at doses 0.8 and 1.6
207 µg/ml ($p <0.05$). In **Fig 3(B)** shows VCAM-1 genes were reduced at concentrations of
208 3.13, 6.25 and 25.0 µg/ml of saffron and 0.4, 0.8 and 1.6 µg/ml of crocin ($*p <0.05$ and
209 $**p <0.01$). **Fig 3(C)** showed that E-selectin gene was significantly reduced at higher
210 doses of saffron (6.25, 12.5 and 25 µg/ml) and crocin (1.6 µg/ml).

211
212 **Fig 3. Effects of various concentrations of saffron crude extract (3.1-25.0 µg/ml) and**
213 **crocin (0.2-1.6 µg/ml) on (A) ICAM-1, (B) VCAM-1 and (C) E-selectin gene regulation**
214 **in HCAECs.** Data are expressed as mean \pm SD. $*p <0.05$ and $**p <0.01$ compared to LPS-
215 stimulated cells. LPS; lipopolysaccharides, HCAECs; human coronary artery endothelial
216 cells.

217
218 **Effects of saffron and crocin on monocyte-endothelial cell**
219 **interaction**

220 Monocyte adhesion assay was performed to explore the effects of saffron and crocin on

221 monocytes and endothelial cell interactions (**Fig 4**). Monocyte U937 cell line showed minimal
222 adherence to the unstimulated HCAECs. After treatment with LPS for 16 hours, the adhesion
223 of U937 monocytes to HCAECs was increased markedly. It was found that saffron and crocin
224 at higher doses lead to the reduction of monocyte adhesion to LPS-stimulated cells. For
225 saffron, significant reductions was observed at 6.25, 12.5 and 25 $\mu\text{g/ml}$ ($*p < 0.05$ and $**p$
226 < 0.01) compared to LPS-stimulated cells. Co-incubation of crocin at 0.4, 0.8 and 1.6 $\mu\text{g/ml}$
227 significantly reduced the adhesion of monocytes to the LPS-stimulated HCAECs ml ($*p$
228 < 0.05 and $**p < 0.01$).

229
230 **Fig 4. Effects of various concentrations of (A) saffron (0.05-25.00 $\mu\text{g/ml}$) and (B) crocin**
231 **(0.003-1.600 $\mu\text{g/ml}$) on monocyte-HCAECs interaction.** Data are expressed as mean \pm SD.
232 $*p < 0.05$ and $**p < 0.01$ compared to LPS-stimulated cells. LPS; lipopolysaccharides,
233 HCAECs; human coronary artery endothelial cells.

234

235 **Discussion**

236 Studies on the effects of crocin on hyperlipidaemic animal models have demonstrated that it
237 has potential anti-atherogenic properties by inhibiting pancreatic lipase and ox-LDL(15,16).
238 At present, studies on anti-atherogenic effects of crocin mainly focused on ox-LDL related
239 pathways. To the best of our knowledge, this is the first report to describe the anti-atherogenic
240 effects of saffron and crocin at molecular and cellular levels. Although other works have
241 published the inhibitory effects of crocin on ICAM-1 and VCAM-1 *in vitro*, its effect on
242 endothelial markers in LPS-induced model has not been widely studied.

243 In the present study, LPS was used to activate an inflammatory response in endothelial cells

244 to mimic the initial stage of atherosclerosis whereby inflammation precedes activation of
245 endothelial biomarkers and accumulation of macrophages in tunica media region of
246 artery(18). This study highlights the role of saffron crude extract and its bioactive
247 compound, crocin, on the atherogenic pathway. Our group demonstrated a dose-dependent
248 decrease in gene and protein expressions of biomarkers of endothelial activation (sICAM-1,
249 sVCAM-1 and E-selectin) in LPS-stimulated HCAECs. This strongly suggests the role of
250 saffron and crocin in attenuating atherogenesis. These results are consistent with the findings
251 reported by other investigators using its active compound, crocin, which improved endothelial
252 function via extracellular receptor kinase (ERK) and protein kinase B (or also known as Akt)
253 signalling pathways in HUVECs(19).

254

255 sICAM-1 is an endothelial and leukocyte associated transmembrane protein renowned for its
256 role in maintaining cell-cell interactions and promoting leukocyte endothelial transmigration.
257 Activated endothelium releases soluble adhesion molecules and is therefore used to measure
258 endothelial activation by measuring fluid-phase of those molecules(20). Previous study
259 reported that another saffron compound, crocetin, can reduce leukocyte adhesion to
260 endothelial cells by decreasing the expression of ICAM-1(18). This study shows that both
261 saffron and crocin reduced the gene and protein expressions of sICAM-1, suggesting its
262 potential role in attenuating monocyte transmigration.

263

264 A study by Zheng et al. (2005) reported that crocetin suppresses VCAM-1 expression due to
265 the inhibition of nuclear factor-kappa beta (NF- κ B) signaling, suggesting it's anti-atherogenic
266 effects in atherosclerotic-induced rabbits(21). Over expression of adhesion molecules,
267 particularly VCAM-1, plays a central role in recruiting circulating monocytes into the intima

268 as an initial event in the pathogenesis of atherosclerosis(22). Our study demonstrated a drop
269 in gene and protein expressions of VCAM-1 which can be extrapolated to denote that
270 recruitment of monocytes into the intima may be inhibited.

271
272 Likewise, E-selectin is a carbohydrate-binding molecule located in endothelial cells, in which
273 it is responsible for the attachment and gradual rolling of leucocytes in an inflammatory
274 response along the vascular wall(23). There is also evidence that the interaction of selectins
275 (E-selectin, P-selectin, L-selectin) with glycosylated ligands of leucocytes mediate rolling and
276 also their behaviour by enabling integrin-dependent reductions in rolling velocities. Selectins
277 also mediate leucocyte adhesion to activated platelets and to other leucocytes. Such results
278 showed that selectins initiate multicellular adhesive and signalling events during pathological
279 inflammation(24). Thus, selectins are known to be endothelial activation biomarkers.

280
281 Recruitment of monocytes is also an important event in the process of atherosclerotic plaque
282 formation. This process is influenced by chemo attractants, adhesion molecules and some
283 receptors. Monocytes differentiate into macrophages in the vessel wall and start to take up
284 lipids, which result in the transformation of macrophage into foam cells³⁰. Scarce data have
285 been reported on the effects of saffron and crocin on monocyte adhesion. In the present study,
286 the unstimulated group showed minimal binding to monocyte U937 cells, whereas co-
287 incubation with LPS markedly increased the adhesion of monocytes to HCAECs. This study
288 revealed that saffron and crocin could inhibit monocytes adhesion to endothelial cells at
289 higher concentrations. The increased potency of saffron and crocin is likely to be due to
290 greater beneficial effects in terms of inhibition of adhesion molecules.

291 This study demonstrates that saffron crude extract and its bioactive compound, crocin are
292 potent anti-atherosclerotic agents for the suppression of endothelial activation biomarkers by
293 reducing the mRNA levels of ICAM-1, VCAM-1 and E-selectin thereby inhibiting its protein
294 synthesis. This in turn explains the reduction in monocyte adhesion as these biomarkers are
295 significant in the recruitment and transmigration of monocytes to the tunica intima. However,
296 saffron crude extracts exhibit better anti-atherosclerotic properties by reducing E-selectin
297 effectively compared to crocin. This may be due to the synergistic effects of other bioactive
298 compound found in the crude extract(25). These findings suggest that, although both
299 compounds show substantial anti-atherogenic properties, saffron appears to exhibit more
300 prominent effect, possibly owing to other bioactive compounds in the crude extract that
301 collectively exerts a more significant anti-atherogenic effects. Future studies to identify other
302 bioactive compounds from crude saffron and determine their effects on atherogenesis would
303 further ascertain the potential of saffron as an anti-atherogenic supplement. In addition, *in*
304 *vivo* studies on crocin and its bioactive compound would determine if in fact, these
305 compounds can be a potential addition to current treatment modalities to the prevention of
306 CAD.

307

308 **Conclusion**

309 Saffron and crocin exhibits potent inhibitory action for endothelial activation, suggesting its
310 potential anti-atherogenic properties where saffron shows better reducing effects on E-
311 selectin. Both compounds also reduce monocyte-endothelial cell interaction. However,
312 saffron exerts more inhibitory effect, suggesting its effectiveness as anti-atherogenesis than its
313 active compound, crocin.

314

315 **Acknowledgement**

316 The authors thank Institute for Medical Molecular Biotechnology (IMMB), Faculty of
317 Medicine, Universiti Teknologi MARA for providing necessary facilities.

318

319 **References**

- 320 1. Khor GL. Cardiovascular epidemiology in the Asia-Pacific region. *Asia Pac J Clin*
321 *Nutr.* 2001;10(2): 76-80.
- 322 2. Mahidin MU. Department of Statistics Malaysia Official Portal. 2018.
- 323 3. Abdullah WMSW, Yusoff YS, Basir N, Yusuf MM. Mortality Rates Due to Coronary
324 Heart Disease by Specific Sex and Age Groups among Malaysians. In: Proceedings of
325 the World Congress on Engineering and Computer Science. San Francisco; 2017.
- 326 4. Cai W, Zhang K, Li P, Zhu L, Xu J, Yang B, et al. Dysfunction of the neurovascular
327 unit in ischemic stroke and neurodegenerative diseases: An aging effect. *Ageing Res*
328 *Rev.* 2017;34:77–87.
- 329 5. Fox CS, Polak JF, Chazaro I, Cupples A, Wolf PA, D'Agostino RA, et al. Genetic and
330 Environmental Contributions to Atherosclerosis Phenotypes in Men and Women.
331 *Stroke.* 2003;34(2):397–401.
- 332 6. Mestas J, Ley K. Monocyte-Endothelial Cell Interactions in the Development of
333 Atherosclerosis. *Trends Cardiovasc Med.* 2008;18(6):228.
- 334 7. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during
335 atherogenesis. *Arterioscler Thromb Vasc Biol.* 2011;31(7):1506–16.
- 336 8. Chistiakov DA, Bobryshev Y V, Orekhov AN. Macrophage-mediated cholesterol
337 handling in atherosclerosis. *J Cell Mol Med.* 2016;20(1):17–28.
- 338 9. Pietro N, Formoso G, Pandolfi A. Physiology and pathophysiology of oxLDL uptake

- 339 by vascular wall cells in atherosclerosis. *Vascul Pharmacol*. 2016;84:1–7.
- 340 10. Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and
341 Obesity. *Circulation*. 2016;133(2):187–225.
- 342 11. De AK, De M. Functional and Therapeutic Applications of Some Important Spices. In:
343 The Role of Functional Food Security in Global Health. West Bengal: Academic Press;
344 2019. p. 499–510.
- 345 12. Vijaya BK. Medicinal uses and pharmacological properties of Crocin sativus linn
346 (Saffron). *Int J Pharm Pharm Sci*. 2011;3(3):22–6.
- 347 13. Melnyk JP, Wang S, Marcone MF. Chemical and biological properties of the world’s
348 most expensive spice: Saffron. *Food Res Int*. 2010;43(8):1981–9.
- 349 14. Bukhari SI, Manzoor M, Dhar MK. A comprehensive review of the pharmacological
350 potential of Crocus sativus and its bioactive apocarotenoids. *Biomed Pharmacother*.
351 2018;98:733–45.
- 352 15. Sheng L, Qian Z, Zheng S, Xi L. Mechanism of hypolipidemic effect of crocin in rats:
353 Crocin inhibits pancreatic lipase. *Eur J Pharmacol*. 2006;543(1–3):116–22.
- 354 16. He S-Y, Qian Z-Y, Tang F-T, Wen N, Xu G-L, Sheng L. Effect of crocin on
355 experimental atherosclerosis in quails and its mechanisms. *Life Sci*. 2005;77(8):907–
356 21.
- 357 17. Liu D-D, Ye Y-L, Zhang J, Xu J-N, Qian X-D, Zhang Q. Distinct Pro-Apoptotic
358 Properties of Zhejiang Saffron against Human Lung Cancer Via a Caspase-8-9-3
359 Cascade. *Asian Pacific J Cancer Prev*. 2014;15:6075–80.
- 360 18. Xiang M, Qian Z-Y, Zhou C-H, Liu J, Li W-N. Crocetin inhibits leukocyte adherence
361 to vascular endothelial cells induced by AGEs. *J Ethnopharmacol*. 2006;107(1):25–31.
- 362 19. Yang H, Li X, Liu Y, Li X, Li X, Wu M, et al. Crocin Improves the Endothelial
363 Function Regulated by Kca3.1 Through ERK and Akt Signaling Pathways. *Cell*

- 364 Physiol Biochem. 2018;46(2):765–80.
- 365 20. Ma Q, Chen S, Klebe D, Zhang JH, Tang J. Adhesion molecules in CNS disorders:
366 biomarker and therapeutic targets. *CNS Neurol Disord Drug Targets*. 2013;12(3):392–
367 404.
- 368 21. Zheng S, Qian Z, Tang F, Sheng L. Suppression of vascular cell adhesion molecule-1
369 expression by crocetin contributes to attenuation of atherosclerosis in
370 hypercholesterolemic rabbits. *Biochem Pharmacol*. 2005;70(8):1192–9.
- 371 22. Čejková S, Králová-Lesná I, Poledne R. Monocyte adhesion to the endothelium is an
372 initial stage of atherosclerosis development. *Cor Vasa*. 2016;58(4):e419–25.
- 373 23. Muller WA. Getting leukocytes to the site of inflammation. *Vet Pathol*. 2013;50(1):7–
374 22.
- 375 24. McEver RP. Selectins: initiators of leucocyte adhesion and signalling at the vascular
376 wall. *Cardiovasc Res*. 2015;107(3):331–9.
- 377 25. Kakisis JD. Saffron: From Greek mythology to contemporary anti-atherosclerotic
378 medicine. *Atherosclerosis*. 2018;268:193–5.
- 379

bioRxiv preprint doi: <https://doi.org/10.1101/2020.01.31.928341>; this version posted January 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.





Fig 1

bioRxiv preprint doi: <https://doi.org/10.1101/2020.01.31.928341>; this version posted January 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.





Fig 2(A,B)



bioRxiv preprint doi: <https://doi.org/10.1101/2020.01.31.928341>; this version posted January 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

Fig 2(C)

bioRxiv preprint doi: <https://doi.org/10.1101/2020.01.31.928341>; this version posted January 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.





Fig 3(A,B)





Fig 3(C)



bioRxiv preprint doi: <https://doi.org/10.1101/2020.01.31.928341>; this version posted January 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.




Fig 4